Cargando…

Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL

BACKGROUND: TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) selectively induces apoptosis in various cancer cells including myeloma (MM) cells. However, the susceptibility of MM cells to TRAIL is largely low in most of MM cells by yet largely unknown mechanisms. Because TNF-α convert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kagawa, Kumiko, Nakano, Ayako, Miki, Hirokazu, Oda, Asuka, Amou, Hiroe, Takeuchi, Kyoko, Nakamura, Shingen, Harada, Takeshi, Fujii, Shiro, Yata, Kenichiro, Ozaki, Shuji, Matsumoto, Toshio, Abe, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289627/ https://www.ncbi.nlm.nih.gov/pubmed/22389670 http://dx.doi.org/10.1371/journal.pone.0031594

Ejemplares similares

TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
por: Takeuchi, Kyoko, et al.
Publicado: (2010)

Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells
por: Nakano, Ayako, et al.
Publicado: (2011)

Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma
por: Ozaki, Shuji, et al.
Publicado: (2019)

Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
por: Harada, Takeshi, et al.
Publicado: (2013)

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
por: Iwasa, Masami, et al.
Publicado: (2019)

Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
por: Harada, Takeshi, et al.
Publicado: (2022)

Primary CD30-positive Diffuse Large B-cell Lymphoma in the Superior Vena Cava
por: Nakamura, Shingen, et al.
Publicado: (2017)

TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
por: Teramachi, Jumpei, et al.
Publicado: (2020)

Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis
por: Sumitani, Ryohei, et al.
Publicado: (2021)

A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration
por: Amachi, Ryota, et al.
Publicado: (2016)

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
por: Ashtar, Mohannad, et al.
Publicado: (2020)

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
por: Bat-Erdene, Ariunzaya, et al.
Publicado: (2016)

Effective impairment of myeloma cells and their progenitors by hyperthermia
por: Miki, Hirokazu, et al.
Publicado: (2017)

Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation
por: Hanson, Derek James, et al.
Publicado: (2015)

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
por: Teramachi, Jumpei, et al.
Publicado: (2023)

The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases
por: Vogl, Thomas J., et al.
Publicado: (2022)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Therapeutic efficacy of the resorcylic acid lactone LL‐Z1640‐2 for adult T‐cell leukaemia/lymphoma
por: Oura, Masahiro, et al.
Publicado: (2023)

The importance of retaining physical functions to prevent skeletal‐related events in multiple myeloma patients with bone disease
por: Miki, Hirokazu, et al.
Publicado: (2022)

Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
por: Ge, Naijian, et al.
Publicado: (2023)

Human immunodeficiency virus-positive secondary syphilis mimicking cutaneous T-cell lymphoma
por: Yamashita, Michiko, et al.
Publicado: (2015)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Projection of Damaged Visual and Language Regions on Low Trail Making Test Part-B Performance in Stroke Patients
por: Nishimura, Ayako, et al.
Publicado: (2022)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
por: Kim, Jung Hee, et al.
Publicado: (2017)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
por: Féray, Cyrille, et al.
Publicado: (2023)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
por: Scartozzi, Mario, et al.
Publicado: (2010)

Constitutional pericentric inversion of chromosome 16, inv(16)(p13.1q22), mimicking acute myeloid leukemia
por: Ozaki, Shuji, et al.
Publicado: (2022)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
por: Wang, Junxiao, et al.
Publicado: (2023)

Efficacy and Safety of TACE Combined with Regorafenib versus TACE in the Third-Line Treatment of Colorectal Liver Metastases
por: Lu, Haohao, et al.
Publicado: (2022)

Autophagy inhibitors regulate TRAIL sensitivity in human malignant cells by targeting the mitochondrial network and calcium dynamics
por: Onoe-Takahashi, Asuka, et al.
Publicado: (2019)

Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety
por: Li, Hui, et al.
Publicado: (2019)

Magnetically Responsive Smart Nanoparticles for Cancer Treatment with a Combination of Magnetic Hyperthermia and Remote-Control Drug Release
por: Hayashi, Koichiro, et al.
Publicado: (2014)

Superparamagnetic Nanoparticle Clusters for Cancer Theranostics Combining Magnetic Resonance Imaging and Hyperthermia Treatment
por: Hayashi, Koichiro, et al.
Publicado: (2013)

Procalcitonin Levels in Post TACE Infection
por: Han, Shugao, et al.
Publicado: (2020)

Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL
por: Nakamura, Hiroe, et al.
Publicado: (2018)

Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma
por: Cai, Yeyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ks0klucmi047e5tqgkdrn3qh3e